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Background: Using a metered-dose inhaler (MDI) beyond the labeled number of actuations 
may result in inadequate dosing of medication, which can lead to poor clinical outcomes. This 
study compared respiratory-related emergency department (ED) visit rates in patients with 
asthma, chronic obstructive pulmonary disease, or both when they used albuterol MDIs with 
versus without dose counters.
Methods: This retrospective study used US claims data to identify patients (ages 4–64 years) 
with asthma, chronic obstructive pulmonary disease, or both, using albuterol MDIs with or 
without an integrated dose counter. The study comprised a 1-year baseline period for patient 
characterization and confounder definition and a 1-year outcome period following the first 
albuterol prescription. The primary end point was the incidence rate of respiratory-related ED 
visits, compared using a reduced zero-inflated Poisson regression model. We also compared 
severe exacerbation rates and rescue medication use.
Results: A total of 93,980 patients were studied, including 67,251 (72%) in the dose counter 
cohort and 26,729 (28%) in the non-dose-counter cohort. The cohorts were broadly similar at 
baseline (55,069 [59%] female patients; median age, 37 years). The incidence rate of respiratory-
related ED visits during the outcome year was 45% lower in the dose counter cohort than in 
the non-dose-counter cohort (adjusted rate ratio: 0.55; 95% confidence interval: 0.47–0.64). 
Exacerbation rates and short-acting β-agonist use were similar between cohorts.
Conclusion: These findings suggest that dose counter integration into albuterol MDIs is 
associated with decreased ED visit rates. The presence of integrated dose counters on rescue 
inhalers can help patients avoid using an empty or near-empty inhaler during exacerbations, 
thereby ensuring available medication for relief of their symptoms. Integrated dose counters on 
rescue MDIs could represent a simple and effective tool to improve clinical outcomes during 
exacerbations, with a potential for cost savings to health care systems.
Keywords: albuterol, asthma, chronic obstructive pulmonary disease, dose counter, inhaler, 
effectiveness
Introduction
Albuterol delivered by conventional “press-and-breathe” metered-dose inhalers (MDIs) 
is the most common symptomatic and rescue therapy for managing reversible bron-
chospasm in asthma and chronic obstructive pulmonary disease (COPD). Although 
dose counters can reliably monitor inhaler use,1–5 they are not currently integrated into 
some rescue MDIs, making it difficult for patients to know when those inhalers are 
empty. In one study, only 8% of patients reported counting the number of actuations 
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and replacing their inhalers at or before the manufacturer’s 
specified maximum number of actuations had been reached.6 
Beyond the labeled number of MDI actuations, the amount of 
active medication available per actuation can vary, resulting 
in a lower than therapeutic dose.2,7 Surveys of patients with 
asthma who use an MDI indicate that >50% of patients do 
not know the number of therapeutic doses remaining in their 
inhalers.6,7 Furthermore, a recent review concluded that up to 
40% of patients actually using an empty or nearly empty MDI 
believe they are taking their asthma medication as prescribed.8
In a recent survey of 224 pediatric and adult patients with 
asthma or COPD, 62% of patients reported feeling anxious 
about not knowing the quantity of medication remaining in 
their inhalers.2 Of the patients surveyed, 72% reported shaking 
their inhalers to assess the quantity of remaining medication, 
and almost one-half (42%) waited until they thought their MDI 
was no longer working before replacing it. The addition of an 
integrated dose counter to MDIs relieved anxiety about run-
ning out of medication for two-thirds of 272 adolescent and 
adult patients with asthma or COPD in a subsequent study.9 
In a cohort study of 1,095 adult patients who utilized the 
emergency department (ED) for asthma, 324 (30%) ran out of 
their inhaled short-acting β-agonist (SABA) or corticosteroid 
medication during the week before their index ED visit.10
Asthma prevalence remains high, affecting almost 26 
million Americans in 2010,11 with approximately two mil-
lion asthma ED visits made each year.11–13 In addition, an 
estimated 13.7 million adults in the US reported having a 
COPD diagnosis in 2011,14 and ED visits for COPD exacer-
bations numbered 1.8 million in 2011, an increase from 1.5 
million in 2006.15
This retrospective database analysis using claims data was 
designed to investigate the impact of integrated dose counter alb-
uterol inhalers on the incidence of  respiratory-related ED visits 
among patients with asthma, COPD, or both. We hypothesized 
that the dose information provided by an integrated dose counter 
could lead to a reduction in the number of respiratory-related ED 
visits by decreasing the use of empty or near-empty canisters.
Methods
Study design
Data for this study were extracted from the Clinformatics™ 
Data Mart retrospective claims database (OptumInsight Life 
Sciences, Eden Prairie, MN, USA), which includes anonymized 
data from an employed, commercially insured United States 
population, and collected between January 2006 and September 
2012. Recorded data include medical claims (primary care and 
secondary care), pharmacy claims, and laboratory test results.
The study comprised a 1-year baseline period for patient 
characterization and confounder definition and 1-year out-
come period for the effectiveness evaluation, with an index 
date defined as the date of the first prescription for albuterol 
(Figure 1). The study data were de-identified, thus written 
informed consent was not possible, and ethics committee 
review was not sought or deemed necessary by the authors.
Patients
Included patients were aged 4–64 years at the index date and 
had a diagnosis of asthma and/or COPD and/or exercise-
induced bronchoconstriction recorded at any time and at least 
one prescription for albuterol. All patients had a first recorded 
prescription for albuterol (index date) between January 1, 
2010, and September 30, 2011, and continuous insurance cov-
erage during the study period. Patients prescribed Ventolin® 
HFA (GlaxoSmithKline Inc., Research Triangle Park, NC, 
USA) were assigned to the dose counter cohort; and patients 
prescribed ProAir® HFA (Teva Respiratory LLC, Horsham, 
PA, USA) or Proventil® HFA (Merck & Co., Inc., Whitehouse 
Figure 1 Study design.
Abbreviations: COPD, chronic obstructive pulmonary disease; SABA, short-acting β-agonist; HFA, hydrofluoroalkane.
Index prescription date
First albuterol prescription
(January 1, 2010–September 30, 2011)
Patients with asthma and/or COPD
• aged 4–64 years
• continuous insurance coverage during
  study period
• no use of any other SABAs
1 year for patient characterization
and baseline confounder definition
Dose counter albuterol
(Ventolin® HFA)
No dose counter albuterol
(ProAir®/Proventil® HFA)
1 year for outcome evaluation
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Station, NJ, USA) were assigned to the non-dose-counter 
cohort. Each of these inhalers delivers 108 μg of albuterol 
sulfate (90 μg of albuterol base) from the mouthpiece per 
actuation. Both the fine-particle mass and the plume vary only 
slightly among the three different inhalers and are monitored 
by the manufacturer and the US Food and Drug Administra-
tion as part of the product’s commercial release.
The exclusion criteria were use of ProAir® HFA (Teva 
Respiratory LLC) or Proventil® HFA (Merck & Co., Inc.) 
(for the dose counter cohort) or the use of Ventolin HFA® 
(GlaxoSmithKline Inc.) (for the non-dose-counter cohort) 
during the outcome period and the use of any other SABA 
during the study period (all patients).
The asthma subpopulation was defined as patients who had 
at least one consultation, inpatient admission, or ED visit for 
asthma recorded at any time during the study period; the COPD 
subpopulation was defined as those who had at least one con-
sultation, inpatient admission, or ED visit for COPD recorded 
at any time during the study period. The concomitant asthma 
and COPD subpopulation was defined as those patients having 
at least one consultation, inpatient admission, or ED visit for 
asthma and COPD and/or codiagnoses recorded at any time dur-
ing the study period. We did not examine results separately for 
the subpopulation with exercise-induced bronchoconstriction.
Outcomes
The primary end point was the incidence rate of respiratory-
related ED visits, defined as ED visits associated with a lower 
respiratory diagnostic code. Secondary end points for patients 
with asthma were the incidence rate of severe exacerbations 
(defined as respiratory-related inpatient admissions/ED visits or 
initiation of acute oral corticosteroids16) and rate of acute respi-
ratory events (defined as occurrence of respiratory-related inpa-
tient admission/ED visits or acute use of oral corticosteroids 
or antibiotics prescribed following a general practitioner visit 
for lower respiratory tract infection). For patients with COPD, 
exacerbations were defined as occurrence of respiratory-related 
inpatient admission/ED visits or acute use of oral corticoste-
roids or antibiotics prescribed following a general practitioner 
visit for lower respiratory tract infection. Additional end points 
included the average daily SABA dose and the probability of 
achieving asthma control (asthma subpopulation only) as risk-
domain asthma control (defined as absence of acute respiratory 
events) and overall asthma control (defined as risk-domain 
asthma control and average daily albuterol dose ≤180 μg).
Statistical analysis
Data were prepared for analysis by investigating outliers 
and the type and reason for missing data; skewed data were 
categorized if appropriate. Because of outliers, all patients 
with >10 ED visits were assigned a value of 10. No imputa-
tion was made for missing values.
We evaluated potential confounders, including those that 
were significantly different at baseline (independent sample 
t-Test, Mann–Whitney U-Test, χ2 test, P<0.10) and baseline 
predictors of outcomes (full multivariable model, P≤0.05). 
Collinearity analysis of confounders (Spearman’s correlation 
coefficients, ρ>0.3) was performed.
A multivariable model was used with stepwise reduction 
to derive the best-fitting model of noncollinear predictors 
(P<0.05). The incidence rate of ED visits was calculated 
using a reduced zero-inflated Poisson regression model. 
Exacerbation rates were compared using a reduced zero-
inflated Poisson regression model, and the odds of achieving 
asthma control were analyzed using a logistic regression 
model. Average daily SABA use was analyzed using a 
reduced ordinal logistic regression model to determine the 
odds ratio (OR) for a higher categorized daily dose com-
pared with a lower categorized daily dose (≤100, 101–200, 
201–400, 401–800, or ≥800 μg albuterol).
Subanalyses were performed for patients with asthma 
only, COPD only, or concomitant asthma and COPD because 
of differences in prescribing indications and outcomes 
definitions.
Results
A total of 93,980 patients ages 4–64 years were included in 
the study (dose counter albuterol cohort: n=67,251 [72%]; 
non-dose-counter albuterol cohort: n=26,729 [28%]) 
( Figure 2). The dose counter and non-dose-counter cohorts 
were broadly similar at baseline (Table 1).
During the outcome period, 341 (0.5%) patients in the 
dose counter cohort overall had a respiratory-related ED 
visit, a significantly smaller proportion than in the non-dose-
counter cohort (304 [1.1%]; P<0.001 for the comparison; 
Table 2). The adjusted rate ratio (RR) for respiratory-related 
ED visits, relative to the non-dose-counter cohort, was 0.55 
(95% confidence interval [CI]: 0.47–0.65; adjusted for base-
line respiratory-related ED visits, respiratory-related inpa-
tient admissions, and asthma consultations; gastroesophageal 
reflux disease diagnosis, rhinitis diagnosis, short-acting 
muscarinic antagonist use, and β-blocker use).
Asthma subpopulation
A total of 75,787 (81%) patients had a diagnosis of asthma, 
including 53,964 (80%) of those in the dose counter cohort 
and 21,823 (82%) of those in the non-dose-counter cohort 
(Table 1). The treatment cohorts were comparable at baseline 
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in terms of demographic characteristics, comorbidities, and 
medication use; a statistically significant difference in median 
age was not clinically significant (Table 1).
Respiratory-related ED visits were recorded during the 
outcome period for 270 (0.5%) and 244 (1.1%) patients with 
asthma in the dose counter and non-dose-counter cohorts, 
respectively (P<0.001; Table 2). Those in the dose counter 
cohort had 51% lower incidence of respiratory-related ED 
visits (adjusted RR: 0.49; 95% CI: 0.41–0.59) (Table 2, 
Figure 3). Average daily SABA dose, severe exacerbation 
rates, and acute respiratory event rates were similar between 
treatment cohorts (Tables 3 and 4, Figure 3). However, cor-
responding with the higher number of ambulatory visits 
resulting in antibiotic prescriptions (Table 3), patients with 
asthma in the dose counter cohort had 4% lower odds of 
achieving risk-domain or overall asthma control than those 
in the non-dose-counter cohort (Table 4, Figure 3).
COPD subpopulation
A total of 6,687 (7%) patients had COPD, including 4,953 
(74%) in the dose counter cohort and 1,734 (26%) in the 
non-dose-counter cohort (Table 1). The treatment cohorts 
were comparable for patients with COPD with regard to 
demographic characteristics, comorbidities, and therapy.
Respiratory-related ED visits were recorded during the 
outcome period for 16 (0.3%) and 23 (1.3%) patients with 
COPD in the dose counter and non-dose-counter cohorts, 
respectively (P<0.001; Table 2). Patients with COPD in the 
Figure 2 Flow diagram of the patient selection process.
Abbreviations: COPD, chronic obstructive pulmonary disease; EIB, exercise-induced bronchoconstriction; SABA, short-acting β-agonist.
Patients in Clinformatics Data Mart
(N=38,400,910)
Excluded:
Never received study drugs
(n=37,178,446)
Excluded:
Prescribed other SABA during outcome year
(n=76,910)
Excluded:
Switch in SABA treatment during outcome
year
(n=27,682)
Excluded:
Insurance coverage not continuous or
aged <4 or >64 years
(n=314,980)
Excluded:
No diagnosis of asthma, COPD, or EIB in
the study period
(n=133,418)
Excluded:
Index prescription date not between
January 1, 2010, and September 30, 2011
(n=575,494)
Prescribed albuterol as Ventolin, ProAir, or Proventil
(n=1,222,464)
Valid index date during study period
(n=646,970)
No other SABA during study period
(n=570,060)
No switch in SABA during outcome year
(n=542,378)
Continuous insurance coverage
during study and aged 4–64 years
(n=227,398)
Final dataset
(n=93,980)
Dose counter
n=67,251 (71.8%)
No dose counter
n=26,729 (28.2%)
 
Jo
ur
na
l o
f A
st
hm
a 
an
d 
Al
le
rg
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
30
-A
ug
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Asthma and Allergy 2016:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
149
Albuterol dose counter in asthma and COPD
T
ab
le
 1
 P
at
ie
nt
 d
em
og
ra
ph
ic
 a
nd
 c
lin
ic
al
 c
ha
ra
ct
er
is
tic
s
C
ha
ra
ct
er
is
ti
c
A
ll 
pa
ti
en
ts
 
N
=
93
,9
80
P
at
ie
nt
s 
w
it
h 
as
th
m
a 
N
=
75
,7
87
P
at
ie
nt
s 
w
it
h 
C
O
P
D
 
N
=
6,
68
7
P
at
ie
nt
s 
w
it
h 
as
th
m
a 
+
 C
O
P
D
 
N
=
6,
42
5
D
os
e 
co
un
te
r
n=
67
,2
51
 (7
1.
6%
)
N
on
-d
os
e 
co
un
te
r
n=
26
,7
29
 (
28
.4
%
)
D
os
e 
co
un
te
r
n=
53
,9
64
 (7
1.
2%
)
N
on
-d
os
e 
co
un
te
r
n=
21
,8
23
 (
28
.8
%
)
D
os
e 
co
un
te
r
n=
4,
95
3 
(7
4.
1%
)
N
on
-d
os
e 
co
un
te
r 
n=
1,
73
4 
(2
5.
9%
)
D
os
e 
co
un
te
r
n=
4,
73
0 
(7
3.
6%
)
N
on
-d
os
e 
co
un
te
r 
n=
1,
69
5 
(2
6.
4%
)
A
ge
 a
t 
in
de
x 
da
te
, m
ed
ia
n 
ye
ar
s 
(IQ
R
)
37
 (
17
–5
0)
38
 (
18
–5
1)
a
35
 (
16
–4
8)
36
 (
18
–4
9)
a
54
 (
48
–6
2)
56
 (
49
–6
0)
a
51
 (
41
–5
8)
52
 (
41
–5
9)
Fe
m
al
e,
 n
 (
%
)
39
,3
52
 (
58
.5
)
15
,7
17
 (
58
.8
)
31
,6
23
 (
58
.6
)
12
,8
42
 (
58
.8
)
2,
64
5 
(5
3.
4)
93
4 
(5
3.
9)
2,
89
7 
(6
1.
2)
1,
02
0 
(6
0.
2)
C
om
or
bi
di
tie
s,
 n
 (
%
)b
O
th
er
 c
hr
on
ic
 r
es
pi
ra
to
ry
 d
is
ea
se
1,
57
1 
(2
.3
)
59
6 
(2
.2
)
80
8 
(1
.5
)
33
0 
(1
.5
)
36
5 
(7
.4
)
13
1 
(7
.6
)
38
0 
(8
)
12
6 
(7
.4
)
R
hi
ni
tis
35
,3
44
 (
52
.6
)
14
,1
89
 (
53
.1
)
29
,4
15
 (
54
.5
)
11
,9
73
 (
54
.9
)
1,
48
0 
(2
9.
9)
51
4 
(2
9.
6)
 
2,
54
5 
(5
3.
8)
91
7 
(5
4.
1)
Ec
ze
m
a
14
,7
27
 (
21
.9
)
5,
95
7 
(2
2.
3)
11
,9
61
 (
22
.2
)
4,
89
9 
(2
2.
4)
84
7 
(1
7.
1)
30
4 
(1
7.
5)
1,
09
0 
(2
3.
0)
42
0 
(2
4.
8)
G
ER
D
11
,7
23
 (
17
.4
)
4,
51
4 
(1
6.
9)
c
8,
72
8 
(1
6.
2)
3,
45
5 
(1
5.
8)
1,
22
2 
(2
4.
7)
43
5 
(2
5.
1)
1,
43
9 
(3
0.
4)
49
8 
(2
9.
4)
Is
ch
em
ic
 h
ea
rt
 d
is
ea
se
3,
22
5 
(4
.8
)
1,
27
0 
(4
.8
)
1,
64
0 
(3
.0
)
68
1 
(3
.1
)
93
8 
(1
8.
9)
32
6 
(1
8.
8)
62
4 
(1
3.
2)
25
1 
(1
4.
8)
U
se
 o
f b
as
el
in
e 
co
m
ed
ic
at
io
n,
 n
 (
%
)
A
ce
ta
m
in
op
he
n
15
,4
54
 (
23
.0
)
5,
82
1 
(2
1.
8)
a
11
,4
54
 (
21
.2
)
4,
50
8 
(2
0.
7)
1,
89
2 
(3
8.
2)
62
2 
(3
5.
9)
1,
63
0 
(3
4.
5)
49
9 
(2
9.
4)
a
N
SA
ID
s
11
,0
47
 (
16
.4
)
4,
23
7 
(1
5.
9)
c
8,
29
5 
(1
5.
4)
3,
27
5 
(1
5.
0)
1,
24
6 
(2
5.
2)
42
1 
(2
4.
3)
1,
18
9 
(2
5.
1)
40
3 
(2
3.
8)
β-b
lo
ck
er
s
3,
43
8 
(5
.1
)
1,
31
5 
(4
.9
)
2,
14
1 
(4
.0
)
84
6 
(3
.9
)
75
0 
(1
5.
1)
26
9 
(1
5.
5)
50
8 
(1
0.
7)
17
6 
(1
0.
4)
N
ot
es
: a
P≤
0.
00
1 
fo
r 
co
m
pa
ri
so
n 
w
ith
 d
os
e 
co
un
te
r 
co
ho
rt
 (
M
an
n–
W
hi
tn
ey
 o
r 
χ2
 t
es
t)
. b
Pr
es
en
ce
 o
f G
P 
vi
si
ts
 in
 t
he
 s
tu
dy
 p
er
io
d 
(2
00
9–
20
12
). 
c P
<
0.
05
 fo
r 
co
m
pa
ri
so
n 
w
ith
 d
os
e 
co
un
te
r 
co
ho
rt
 (
M
an
n–
W
hi
tn
ey
 o
r 
χ2
 t
es
t)
.
A
bb
re
vi
at
io
ns
: C
O
PD
, c
hr
on
ic
 o
bs
tr
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e;
 G
ER
D
, g
as
tr
oe
so
ph
ag
ea
l r
efl
ux
 d
is
ea
se
; G
P,
 g
en
er
al
 p
ra
ct
ic
e;
 IQ
R
, i
nt
er
qu
ar
til
e 
ra
ng
e;
 N
SA
ID
s,
 n
on
st
er
oi
da
l a
nt
i-i
nfl
am
m
at
or
y 
dr
ug
s.
T
ab
le
 2
 H
ea
lth
 c
ar
e 
re
so
ur
ce
 u
til
iz
at
io
n 
at
 b
as
el
in
e 
an
d 
du
ri
ng
 t
he
 o
ut
co
m
e 
pe
ri
od
V
ar
ia
bl
e
A
ll 
pa
ti
en
ts
 
N
=
93
,9
80
P
at
ie
nt
s 
w
it
h 
as
th
m
a 
N
=
75
,7
87
P
at
ie
nt
s 
w
it
h 
C
O
P
D
 
N
=
6,
68
7
P
at
ie
nt
s 
w
it
h 
as
th
m
a 
+
 C
O
P
D
 
N
=
6,
42
5
D
os
e 
co
un
te
r
n=
67
,2
51
 
(7
1.
6%
)
N
on
-d
os
e 
co
un
te
r 
n=
26
,7
29
 (
28
.4
%
)
P-
va
lu
ea
D
os
e 
co
un
te
r
n=
53
,9
64
 
(7
1.
2%
)
N
on
-d
os
e 
co
un
te
r 
n=
21
,8
23
 (
28
.8
%
)
P-
va
lu
ea
D
os
e 
co
un
te
r
n=
4,
95
3 
(7
4.
1%
)
N
on
-d
os
e 
co
un
te
r
n=
1,
73
4 
(2
5.
9%
)
P-
va
lu
ea
D
os
e 
co
un
te
r
n=
4,
73
0 
(7
3.
6%
)
N
on
-d
os
e 
co
un
te
r
n=
1,
69
5 
(2
6.
4%
)
P-
va
lu
ea
R
es
pi
ra
to
ry
-r
el
at
ed
 E
D
 v
is
its
, n
 (
%
)
Ba
se
lin
e 
≥1
40
3 
(0
.6
)
39
3 
(1
.5
)
<
0.
00
1
32
7 
(0
.6
)
31
7 
(1
.5
)
<
0.
00
1
28
 (
0.
6)
29
 (
1.
7)
<
0.
00
1
31
 (
0.
7)
28
 (
1.
7)
<
0.
00
1
O
ut
co
m
e 
≥1
34
1 
(0
.5
)
30
4 
(1
.1
)
<
0.
00
1
27
0 
(0
.5
)
24
4 
(1
.1
)
<
0.
00
1
16
 (
0.
3)
23
 (
1.
3)
<
0.
00
1
42
 (
0.
9)
23
 (
1.
4)
0.
05
8
R
es
pi
ra
to
ry
-r
el
at
ed
 in
pa
tie
nt
 a
dm
is
si
on
s,
 n
 (
%
)
Ba
se
lin
e 
≥1
1,
89
2 
(2
.8
)
78
1 
(2
.9
)
0.
36
6
1,
06
2 
(2
.0
)
46
8 
(2
.1
)
0.
11
8
47
1 
(9
.5
)
16
7 
(9
.6
)
0.
88
2
33
5 
(7
.1
)
13
9 
(8
.2
)
0.
13
1
O
ut
co
m
e 
≥1
2,
26
4 
(3
.4
)
89
1 
(3
.3
)
0.
80
0
1,
36
6 
(2
.5
)
56
8 
(2
.6
)
0.
57
2
1,
21
6 
(2
4.
6)
42
3 
(2
4.
4)
0.
89
6
38
9 
(8
.2
)
14
5 
(8
.6
)
0.
67
2
N
ot
e:
 a χ
2  t
es
t.
A
bb
re
vi
at
io
ns
: C
O
PD
, c
hr
on
ic
 o
bs
tr
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e;
 E
D
, e
m
er
ge
nc
y 
de
pa
rt
m
en
t.
 
Jo
ur
na
l o
f A
st
hm
a 
an
d 
Al
le
rg
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
9.
13
3.
14
8.
27
 o
n 
30
-A
ug
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Journal of Asthma and Allergy 2016:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
150
Price et al
dose counter cohort had 60% lower adjusted respiratory-
related ED visit rates versus patients in the non-dose-counter 
cohort (adjusted RR: 0.40; 95% CI: 0.22–0.75) (Table 2). 
Other COPD outcomes were comparable between cohorts, 
including COPD exacerbation rates (adjusted RR: 1.05; 95% 
CI: 0.97–1.13) and average daily SABA dose (adjusted OR: 
1.08; 95% CI: 0.94–1.25) (Table 4).
Asthma and COPD subpopulation
A total of 6,425 (7%) patients had a codiagnosis of asthma 
and COPD, including 4,730 (7%) of those in the dose coun-
ter cohort and 1,695 (6%) of those in the non-dose-counter 
cohort (Table 1). The treatment cohorts were comparable 
with regard to demographic characteristics, comorbidities, 
and therapy.
There was no significant difference between the two 
cohorts in the unadjusted rate of outcome respiratory-related 
ED visit rates for patients with asthma and COPD (reported 
for 42 [0.9%] and 23 [1.4%] in dose counter and non-dose-
counter cohorts, respectively; P=0.058; Table 2. The adjusted 
RR was 0.70 (95% CI: 0.43–1.16). Outcomes were compa-
rable between treatment cohorts in terms of exacerbation rates 
(adjusted RR: 1.06 [0.97–1.16]) and average daily SABA 
dose (adjusted OR: 1.05; 95% CI: 0.92–1.20; Table 4).
Discussion
In this investigation of the impact of an integrated 
dose counter in albuterol inhalers, the incidence rate of 
Figure 3 Adjusted outcome measures for study end points over 1 year after the index date for patients with asthma.
Notes: The non-dose-counter cohort is the comparator, with adjusted risk ratio/odds ratio set at 1.0. Adjusted for the following baseline variables: aSevere exacerbations, 
asthma consultations, ischemic heart disease diagnosis, acetaminophen use. bSevere exacerbations, age, gastroesophageal reflux disease diagnosis, acetaminophen use. cAcute 
oral corticosteroid courses, antibiotics prescribed at lower respiratory consultation, asthma consultations. dAntibiotics prescribed at lower respiratory consultation, acute 
oral corticosteroid courses, gastroesophageal reflux disease diagnosis. eAge. fAge, respiratory prescriptions, antibiotics prescribed at lower respiratory consultation.
Abbreviations: CI, confidence interval; ED, emergency department; SABA, short-acting β-agonist
Respiratory-related ED visits
No dose counter = 1.00
Adjusted rate/odds ratios (95% Cl) for the dose counter cohort
Severe exacerbations
Acute respiratory events
Risk-domain asthma control
Overall asthma control
Higher vs lower SABA dose
0.4 0.6
Lower with dose counter
0.49 (0.41–0.59)a
1.01 (0.98–1.05)b
1.02 (0.99–1.05)c
0.96 (0.93–1.00)d
0.96 (0.92–0.99)e
1.02 (0.97–1.06)f
0.8 1 1.4
 respiratory-related ED visits during the outcome year was 
estimated to be 45% lower in the dose counter cohort than 
in the non-dose-counter cohort. This result remained sig-
nificant after splitting the population by single diagnosis: a 
51% lower incidence rate was seen in patients with asthma 
and a 60% lower rate in those with COPD. There was no 
statistically significant difference in ED visit incidence rate 
between cohorts for the small subpopulation of patients with 
codiagnosis of asthma and COPD.
Using a dose counter device was not associated with 
changes in indicators of disease control, including average 
daily SABA dose, which was not significantly different 
between the dose counter and non-dose-counter cohorts, for 
either the overall population or the subpopulations. We can 
speculate that the lack of difference in exacerbations may be 
because ED visits were relatively low in number as compared 
with the other components of the composite exacerbation 
variables, which included inpatient admissions and oral cor-
ticosteroid courses in the case of asthma exacerbations, and 
also antibiotics prescribed following a general practitioner 
visit for lower respiratory tract infection in the case of COPD 
exacerbations. Moreover, patients in the dose counter cohort 
of the asthma subpopulation had 4% lower odds of achiev-
ing overall asthma control in the outcome period. This was 
because they had a higher number of ambulatory visits for 
lower respiratory tract infections with antibiotic prescriptions, 
a component of the composite asthma control measures. We 
have no certain explanation for the latter finding.
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or
 w
ith
 d
os
e 
≤1
0 
µg
 b
ut
 s
tr
en
gt
h 
≥5
 µ
g 
an
d 
a 
sa
m
e-
da
y 
ge
ne
ra
l p
ra
ct
ic
e 
vi
si
t f
or
 lo
w
er
 r
es
pi
ra
to
ry
 tr
ac
t i
nf
ec
tio
n.
A
bb
re
vi
at
io
ns
: C
O
PD
, c
hr
on
ic
 o
bs
tr
uc
tiv
e 
pu
lm
on
ar
y 
di
se
as
e;
 G
P,
 g
en
er
al
 p
ra
ct
ic
e;
 IC
S,
 in
ha
le
d 
co
rt
ic
os
te
ro
id
; L
A
BA
, l
on
g-
ac
tin
g 
β-a
go
ni
st
; 
LA
M
A
, l
on
g-
ac
tin
g 
m
us
ca
ri
ni
c 
an
ta
go
ni
st
; 
LT
R
A
, l
eu
ko
tr
ie
ne
 r
ec
ep
to
r 
an
ta
go
ni
st
; 
O
C
S,
 o
ra
l 
co
rt
ic
os
te
ro
id
; S
A
BA
, s
ho
rt
-a
ct
in
g 
β-a
go
ni
st
; S
A
M
A
, s
ho
rt
-a
ct
in
g 
m
us
ca
ri
ni
c 
an
ta
go
ni
st
.
T
ab
le
 3
 (
Co
nt
in
ue
d)
Our data suggest that dose counters may enable patients 
to directly know when their rescue medication is empty and 
thus avoid using empty inhalers during exacerbations. This 
knowledge may help to reduce the need for acute health care 
interventions such as ED visits. However, although this sig-
nificant difference (halving) in ED visits has important clinical 
consequences, ED visits were a relatively rare event (absolute 
rates were low) in a relatively mild disease population (those 
receiving first prescribed rescue medication in the study period 
and likely to be newly diagnosed patients). For patients with 
more severe disease, such a reduction in costly ED visits may be 
more important because higher health care costs are associated 
with greater asthma severity,17 and a substantial proportion of 
the health care costs associated with COPD accrue from patients 
with frequent ED visits for acute COPD exacerbations.18
Prior studies of patients with asthma or COPD have reported 
high levels of patient satisfaction (>90%) with the use of dose 
counters on MDIs containing rescue medication, specifically 
with regard to the ability to know when the inhaler should be 
replaced.1,2 In a recent online survey of 590 adults and children 
with asthma, many of whom were found to have empty or 
expired reliever inhalers, the addition of a dose counter was 
named most frequently as a means of improving satisfaction 
with their reliever inhalers.19 In the future, newer technologies 
may improve patient engagement with their therapy, and gains 
in disease management may be possible if the rescue dosing 
data are better integrated into practice. For example, in a recent 
study, telemonitoring of SABA use via a patient-facing smart-
phone app, with dose reporting to providers, was associated 
with decreased use of rescue medication and improved asthma 
control among those adults initially lacking asthma control.20
An important limitation of this study is the nonrandom 
treatment assignment, an issue common to all observational 
studies.21,22 Although adjustment for potential confounders 
was performed wherever feasible, there remains the possibil-
ity of unrecognized bias or confounding. In addition, detailed 
patient characterization was not possible from the data. For 
example, we could not determine whether patients with both 
asthma- and COPD-related claims should have been defined 
as having asthma-COPD overlap syndrome.23 Moreover, infor-
mation on spacer use would have been of interest to consider.
Strengths of the study include, 1) the large patient popula-
tion, 2) the fact that all patients were members of an employed, 
commercially insured population (thus of similar socioeco-
nomic status), and 3) the fact that the two cohorts (dose counter 
and non-dose-counter) were in the same insurance plan (thus 
affordability was likely similar for all). However, the gener-
alizability of study findings is limited to patients receiving a 
first prescription for albuterol and to employed, commercially 
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Table 4 Asthma and COPD exacerbations at baseline and during the outcome period
Patients with asthma 
N=75,787
Patients with COPD 
N=6,687
Patients with asthma + COPD 
N=6,425
Dose counter
n=53,964 (71.2%)
Non-dose counter
n=21,823 (28.8%)
Dose counter
n=4,953 (74.1%)
Non-dose counter
n=1,734 (25.9%)
Dose counter
n=4,730 (73.6%)
Non-dose counter
n=1,695 (26.4%)
Severe asthma exacerbations, n (%)
Baseline
0 44,177 (81.9) 17,746 (81.3) N/A 3,331 (70.4) 1,159 (68.4)
1 8,126 (15.1) 3,424 (15.7) 1,047 (22.1) 395 (23.3)
2–3 1,486 (2.8) 571 (2.6) 295 (6.2) 112 (6.6)
≥4 175 (0.3) 82 (0.4) 57 (1.2) 29 (1.7)
Outcome
0 44,558 (82.6) 18,035 (82.6) 3,280 (69.3) 1,173 (69.2)
1 7,264 (13.5) 2,957 (13.5) 942 (19.9) 356 (21)
2–3 1,909 (3.5) 729 (3.3) 422 (8.9) 128 (7.6)
≥4 233 (0.4) 102 (0.5) 86 (1.8) 38 (2.2)
Acute respiratory events, n (%)
Baseline
0 35,065 (65.0) 14,333 (65.7) 2,031 (41.0) 717 (41.3) 2,075 (43.9) 729 (43.0)
1 15,113 (28.0) 5,983 (27.4) 2,109 (42.6) 759 (43.8) 1,775 (37.5) 640 (37.8)
2–3 3,537 (6.6) 1,390 (6.4) 726 (14.7) 233 (13.4) 770 (16.3) 279 (16.5)
≥4 249 (0.5) 117 (0.5) 87 (1.8) 25 (1.4) 110 (2.3) 47 (2.8)
Outcome
0 39,969 (74.1) 16,367 (75.0) 2,905 (58.7) 1,052 (60.7) 2,417 (51.1) 919 (54.2)
1 10,468 (19.4) 4,145 (19.0) 1,321 (26.7) 458 (26.4) 1,364 (28.8) 475 (28.0)
2–3 3,188 (5.9) 1,179 (5.4) 613 (12.4) 180 (10.4) 790 (16.7) 235 (13.9)
≥4 339 (0.6) 132 (0.6) 114 (2.3) 44 (2.5) 159 (3.4) 66 (3.9)
Note: There were no significant differences between cohorts (χ2 test).
Abbreviations: COPD, chronic obstructive pulmonary disease; N/A, not applicable.
insured patients such as those who were included in the data-
base. Further studies are needed to explore the use of integrated 
dose counters for other patient populations.
Conclusion
We found that the integration of dose counters into rescue 
inhaler devices is associated with decreased ED visit fre-
quency. The presence of integrated dose counters on rescue 
inhalers can help patients avoid using an empty or near-empty 
inhaler during exacerbations, thereby ensuring available 
medication for relief of their symptoms. The integration of 
dose counters on rescue MDIs could represent a simple and 
effective tool to improve clinical outcomes during exacerba-
tions, with a potential for cost savings to health care systems.
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